Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) PT at $12.33

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $12.3333.

Several research analysts recently weighed in on the company. Edward Jones began coverage on Evaxion A/S in a report on Thursday, October 30th. They issued a “buy” rating and a $10.00 price target for the company. Jones Trading upgraded shares of Evaxion A/S to a “strong-buy” rating in a research report on Wednesday, October 29th. Lake Street Capital increased their target price on shares of Evaxion A/S from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Evaxion A/S in a research note on Monday, October 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th.

Evaxion A/S Stock Down 2.6%

Evaxion A/S stock opened at $3.31 on Monday. Evaxion A/S has a 52 week low of $1.20 and a 52 week high of $12.15. The stock has a 50-day moving average price of $4.70 and a 200 day moving average price of $4.57. The company has a market capitalization of $27.61 million, a price-to-earnings ratio of -8.49 and a beta of 0.29.

Institutional Investors Weigh In On Evaxion A/S

A hedge fund recently bought a new stake in Evaxion A/S stock. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 8,000 shares of the company’s stock, valued at approximately $38,000. Northwestern Mutual Wealth Management Co. owned 0.10% of Evaxion A/S as of its most recent filing with the SEC. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.